iPSC_FB_F19901C3_TTN_E357_E33459*_N33456N_C30
BBANTWi012-A-3
General
Cell Line |
|
| hPSCreg name | BBANTWi012-A-3 |
| Cite as: | BBANTWi012-A-3 (RRID:CVCL_E3QX) |
| Alternative name(s) |
iPSC_FB_F19901C3_TTN_E357_E33459*_N33456N_C30
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
BBANTWi012-A-4 (iPSC_FB_F19901C3_TTN_E357_V33467*_N33456N_C3) BBANTWi012-A-1 (TTN_E48_V4623*) BBANTWi012-A-2 (iPSC_FB_F19901C3_TTN_E48_L4612*) BBANTWi012-A (F1990.01 C3) BBANTWi012-A-5 (iPSC_F199001_C3_CRISPR_CACNA1C_T330M_HMZ_C6) BBANTWi012-A-6 (iPSC_F199001_C3_CRISPR_CACNA1C_T330M_HTZ_C11.2) UCSFi001-A-27 (AICS-0048-039) CBRCULi016-A-1 (SCN5A p.R219H-14C-ISO) Donor's gene variants: SCN5A Donor diseases: dilated cardiomyopathy WAe009-A-1E (TBX20-KO) WAe009-A-1H (MYL3-KO) UCSDi001-A-1 (UCSD242i-LQT1-1, LQT1_2_5_iPSC_P17) UCSDi001-A-2 (LQT3_35_iPSC_P15, UCSD243i-LQT3-1) UCSDi001-A-3 (LQT3_4_28_Homo_52_iPSC_P15, UCSD244i-LQT3-2) UCSDi001-A-4 (UCSD245i-CNTL-1, T036_SNP1_Het_1_iPSC_P15_R01) UCSDi001-A-5 (UCSD246i-CNTL-2, T036_SNP1_Het_3_iPSC_P16_R01) WAe009-A-36 (JPH2-KO) NUIGi038-B-1 (CR.LQTH002Cx-A17) NUIGi038-B-2 (CR.LQTH002Cx-A21) NUIGi038-B-3 (CR.LQTH002Cx-3A15) NUIGi038-B-4 (CR.LQTH002Cx-3A18) WAe009-A-62 (KCNQ1 KO) WAe009-A-1Y (TRPV2-KO) UKEi001-A-2 (Biallelic NRAP-KO) UKEi001-A-3 (NRAP-OE) |
| Last update | 10th May 2024 |
| User feedback | |
Provider |
|
| Generator | Biobank Antwerpen (BBANTW) |
| Owner | Center of Medical Genetics Antwerp (CMGANT) |
| Distributors | |
| Derivation country | Belgium |
External Databases |
|
| BioSamples | SAMEA115501496 |
| Cellosaurus | CVCL_E3QX |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA115545255 |
Ethics
Also have a look at the ethics information for the parental line
BBANTWi012-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
BBANTWi012-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™ Flex
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
Yes |
| CXCR4 |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| HAND1 |
Yes |
| NKX2-5 |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| HES5 |
Yes |
| MAP2 |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XY. No clinically significant abnormalities observed.
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Genotyped with Illumina's HumanCytoSNP-12 v2.1. No clinically significant CNVs observed |
Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.